Novo Nordisk on Wednesday managed the unusual feat of seeing its stock price rise after reducing its earnings outlook. But ...

Novo Nordisk slashed its 2025 sales forecast citing lower-than-expected penetration of its branded GLP-1 weight loss and ...

European stock markets are poised for a mixed and cautious opening on Wednesday as investors globally turn their full ...

Obesity drugmaker Novo Nordisk has today downgraded its 2025 sales forecast, ending a four-year stretch of steady guidance ...

Novo Nordisk now expects sales to grow 13% to 21% in constant currencies this year, from 16% to 24% previously. Operating profit should grow 16% to 24% compared with a previous target of 19% to 27%.

Obesity drugmaker Novo Nordisk downgraded its 2025 sales forecast on Wednesday, ending a four-year stretch of steady guidance ...

Novo Nordisk (NYSE:NVO) trimmed its full-year 2025 sales and profit forecast on Wednesday, citing weaker-than-expected U.S.

First-quarter sales rise 18 per cent but Danish pharma group blames custom preparations at pharmacies for weaker take-up ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

COPENHAGEN (Reuters) -Obesity drugmaker Novo Nordisk on Wednesday cut its full-year sales and profit outlook amid lacklustre ...